Flu shot, Pandemrix®, might reduce diabetes risk in children, study found.

What do you use to diagnose prediabetes a majority of the time? 1) HbA1c 2) Fasting BG 3) IGTT 4) Other Follow the link to see how you compare to your colleagues.

A 43-year-old patient with a 2-year history of type 2 diabetes presents to your office for a follow-up visit. She is a highly motivated patient and doesn’t have any significant co-morbidities, so together, you have set a target A1C= 6.5%. Her current medications are metformin and sulfonylurea. Despite her good efforts, her current A1C is 7.3%. You would like to add a third agent to her regimen, however, she is concerned about any additional weight gain as she has gained a few pounds since starting the sulfonylurea. Which drug class would you add to minimize any additional weight gain? A. Basal insulin B. GLP-1 agonist C. Thiazolidine D. DPP-4 Inhibitor

The FDA has approved an auto-injector and new formulation of a once-weekly treatment for type 2 diabetes from AstraZeneca. Bydureon BCise offers a single-dose auto-injector for adults with type 2 diabetes. Bydureon BCise features a unique continuous-release microsphere technology delivery system that provides consistent levels of the product’s active ingredient, exenatide. The new formulation has shown the ability to reduce blood sugar levels alongside weight loss, despite not being a weight loss medication.

Joel Goldsmith is the Senior Director of Digital Platforms at Abbott Diabetes Care, which is focused on designing, developing, and commercializing software-based products and services that drive trial and sustained utilization of ADC's sensor-based glucose monitoring solutions. He and his team created the FreeStyle Libre system, which comprises a tiny glucose sensor (0.2 inches in length, about the thickness of a hair) inserted through the skin and connected to a small, water resistant, plastic patch on the skin’s surface.

In this Exclusive Interview, Joel Goldsmith talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about the new Freestyle Lite and Freestyle Pro CGM systems, their benefit to patients as well as clinicians, and the response thus far.

In this Exclusive Interview, Joel Goldsmith discusses how CGMs are changing diabetes management, including the Freestyle Libre system, intended for use by patients, and Freestyle Libre Pro, a solution that’s designed for clinicians.

In part 1 of this Exclusive Interview, Joel Goldsmith talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about what happened to an earlier Abbott product, the Navigator, and explains the latest CGM products, Freestyle Libre and Freestyle Libre Pro.

In part 2 of this Exclusive Interview, Joel Goldsmith talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about the differences between the Freestyle Libre and Pro systems, once of which is patient-focused, the other for clinician monitoring.

In part 3 of this Exclusive Interview, Joel Goldsmith explains the use and affordability of the Freestyle Libre system in a conversation with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California.